Artivion, Inc. (NYSE:AORT) Receives $49.11 Average Target Price from Brokerages

Artivion, Inc. (NYSE:AORT) has been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $49.1143.

Several equities research analysts have recently issued reports on the company. JMP Securities lifted their target price on Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a report on Friday, October 10th. Citigroup reaffirmed an “outperform” rating on shares of Artivion in a research note on Friday, October 10th. Oppenheimer reaffirmed an “outperform” rating and issued a $50.00 price objective on shares of Artivion in a research note on Friday, November 7th. Citizens Jmp increased their target price on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Finally, Wall Street Zen upgraded shares of Artivion from a “buy” rating to a “strong-buy” rating in a research report on Sunday, December 21st.

Artivion Price Performance

Shares of NYSE:AORT opened at $43.36 on Monday. The firm has a market cap of $2.05 billion, a price-to-earnings ratio of -180.65 and a beta of 1.59. The firm has a fifty day moving average price of $45.39 and a 200 day moving average price of $41.38. Artivion has a fifty-two week low of $21.97 and a fifty-two week high of $48.25. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.88 and a current ratio of 3.93.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.14 by $0.02. Artivion had a negative net margin of 2.16% and a positive return on equity of 5.98%. The business had revenue of $113.39 million for the quarter, compared to analysts’ expectations of $110.71 million. The business’s revenue was up 18.9% on a year-over-year basis. As a group, sell-side analysts expect that Artivion will post 0.37 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Artivion news, CEO James P. Mackin sold 34,210 shares of the business’s stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $45.86, for a total transaction of $1,568,870.60. Following the transaction, the chief executive officer owned 800,993 shares in the company, valued at $36,733,538.98. The trade was a 4.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Jean F. Holloway sold 10,000 shares of the business’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $46.18, for a total value of $461,800.00. Following the transaction, the senior vice president owned 169,169 shares of the company’s stock, valued at approximately $7,812,224.42. The trade was a 5.58% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 234,511 shares of company stock worth $10,612,452. 7.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in AORT. Caitong International Asset Management Co. Ltd purchased a new stake in Artivion in the 3rd quarter valued at about $27,000. Aster Capital Management DIFC Ltd raised its stake in shares of Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after acquiring an additional 519 shares in the last quarter. USA Financial Formulas boosted its holdings in shares of Artivion by 163.5% in the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after purchasing an additional 703 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after purchasing an additional 538 shares during the period. Finally, State of Wyoming bought a new position in Artivion in the third quarter worth approximately $80,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.